Levoketoconazole Dosing With MATE1 and OCT2 Drug Interaction Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Cushing's syndrome, such as ketoconazole, pose risks including hepatotoxicity and drug interactions, necessitating a safer and more effective alternative.
Innovation Solution
Administering levoketoconazole, a 2S,4R enantiomer of ketoconazole, in combination with a titration scheme and reduced doses of MATE1 or OCT2 substrates or metformin to manage Cushing's syndrome and related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ketoconazole is used to treat Cushing's syndrome, then cortisol synthesis is inhibited and hypercortisolism is reduced, but hepatotoxicity and drug interactions occur
Solution Approach 1:
The patent segments ketoconazole into its two enantiomers (2S,4R-levoketoconazole and 2R,4S-isoketoconazole) and identifies that one enantiomer (levoketoconazole) provides the desired therapeutic effect with reduced adverse effects compared to the racemic mixture. This segmentation allows for selective use of the beneficial enantiomer while avoiding the harmful effects associated with the other enantiomer or the mixture.
Solution Approach 2:
The patent changes the stereochemical parameter of ketoconazole from a racemic mixture to a single enantiomer (2S,4R configuration). This parameter change results in levoketoconazole having higher potency for cortisol synthesis inhibition and reduced hepatotoxicity and drug interaction potential compared to the racemic ketoconazole.
2Reliability
If levoketoconazole is administered to achieve higher plasma concentrations and more potent cortisol synthesis inhibition, then therapeutic efficacy is improved, but potential for drug interactions with MATE1 and OCT2 substrates increases
Solution Approach 1:
The patent applies preliminary action by reducing the dosage of MATE1 and OCT2 substrates (such as metformin) before or during the initiation of levoketoconazole therapy. This preemptive dose reduction prevents excessive accumulation of the co-administered drug and avoids adverse interactions, allowing the patient to receive the full therapeutic benefit of levoketoconazole without the harmful effects of drug interactions.
Solution Approach 2:
The patent implements feedback control through therapeutic drug monitoring and dose adjustment. The dosage of MATE1 and OCT2 substrates is reduced based on the presence and dosage of levoketoconazole, creating a feedback mechanism that maintains safe drug levels and prevents toxic interactions while preserving therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Levoketoconazole effectively reduces cortisol levels with minimized side effects and drug interactions, providing a safer therapeutic option for Cushing's syndrome and related disorders.
Implementation Method 1
Ketoconazole reduces or inhibits adrenal steroid production by inhibiting several adrenal steroidogenic enzymes, including CYP17A1 (also known as 17α-hydroxylase) and CYP11B1 (also known as mitochondrial 11β-hydroxylase)
Implementation Method 2
Ketoconazole also potently inhibits several drug-metabolizing enzymes, including CYP3A4, with a potential for marked drug interactions
Data Source
AI summary
Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.